Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026
Zentalis Pharmaceuticals presented Phase 1b MUIR trial data at ASCO 2026 showing azenosertib plus paclitaxel achieved a 39.1% overall response rate in platinum-resistant ovarian cancer, outperforming historical paclitaxel monotherapy benchmarks of ~30%. The combination demonstrated a manageable safety profile with low rates of high-grade adverse events, and the 250 mg intermittent dose cohort showed a 50% response rate with a 9.2-month median duration of response.
Key figures
- Drug Name
- azenosertib
- Phase Of Trial
- Phase 1b
- Orr all comer
- 39.1%
- Patient count
- 46
- Cbrr all comer
- 58.7%
- Median pfs all comer
- 7.3 months
- Orr optimal dose cohort
- 50.0%
- Median dor optimal dose cohort
- 9.2 months
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.